Artelus is an AI-driven healthcare technology company focused on preventing avoidable blindness through advanced retinal imaging, Artificial Intelligence, and accessible eye care solutions. The company develops portable retinal screening systems, AI-powered diagnostics, and OCT imaging solutions designed to support early detection of retinal diseases such as diabetic retinopathy, glaucoma, and other vision-threatening conditions. Artelus aims to make retinal diagnostics more accessible, affordable, accurate, and scalable for healthcare professionals, clinics, hospitals, screening programs, and underserved communities through solutions like Artelus DRISTi AI, Artelus Fundus, and Artelus EZZEntial™ OCT.

Artelus aims to democratize healthcare and bring advanced retinal diagnostics to the “Forgotten Billions” using artificial intelligence and affordable ophthalmic technology. The company focuses on enabling early detection of retinal diseases, including diabetic retinopathy, through AI-powered retinal analysis that delivers accurate screening results in approximately 60 seconds, supporting faster diagnosis, timely intervention, and more accessible eye care.

DRISTi AI is Artelus’ AI-powered Diabetic Retinopathy screening solution designed for rapid and early detection of diabetic eye disease during routine screenings. It works offline and is built for deployment even in remote or underserved areas.

DRISTi AI offers several capabilities designed to make retinal screening faster, accessible, and operator-independent.

• Automatic image capture for operator-independent screening.
• Fully offline AI with no internet required.
• Trained on 100,000+ retinal images.
• Instant AI reports at the point of care.
• Wider retinal coverage with montage imaging.
• Patient data remains local with no cloud transfer, ensuring greater privacy and security.
• DR grading and pathology detection in one report.
• High-quality non-mydriatic retinal imaging.
• Portable and scalable for any care setting.
• Supports early detection of retinal diseases.

Artelus DRISTi AI is officially validated to detect Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME).

• Glaucoma risk
• Age-related Macular Degeneration (ARMD / AMD)
• Drusen
• Central Serous Retinopathy (CSR)
• Choroidal Neovascularization (CNV)
• Macular Hole
• Other retinal abnormalities

Artelus OCT systems are designed to provide portable, lightweight, and rapid retinal imaging capabilities suitable for a variety of clinical and outreach environments.

• Portable OCT imaging
• Lightweight
• Suitable for bedside imaging
• Widefield imaging
• Functional on non-dilated pupils
• Optimized for rapid image capture
• AI-enabled for retinal analysis

Yes. Artelus has developed portable OCT solutions that can fit into a backpack, making them suitable for clinical, outreach, and screening environments.

• Bedside imaging
• Rural outreach
• Screening camps
• ROP evaluations
• Imaging uncooperative or critically ill patients

Yes. Artelus provides offline AI-enabled screening capabilities, enabling retinal diagnostics even in areas with limited internet connectivity.

Some of the major differentiators of Artelus include:

• Portable and lightweight systems
• Offline AI functionality
• Truly non-mydriatic imaging
• No dark room required
• Auto-alignment and auto-capture technology
• Operator-independent screening
• AI-assisted DR grading
• Multi-pathology retinal detection
• Battery-operated devices
• Rapid screening and report generation
• High-quality gradable images
• Remote operability

Artelus AI includes explainable AI features that generate heatmaps highlighting regions of interest in retinal scans. This helps clinicians understand AI-supported findings more transparently.

AI-powered diabetic retinopathy screening uses artificial intelligence to analyze retinal images and identify signs that may indicate diabetic retinopathy, helping prioritize patients for further clinical evaluation.

Artelus solutions are designed for a range of healthcare professionals, organizations, and community-based screening programs.

• Ophthalmologists
• Retina specialists
• Eye hospitals
• Clinics
• NGOs
• Screening camps
• Teleophthalmology programs

Yes. Artelus solutions are built for community eye screening and outreach programs, especially in underserved regions.

Yes. Artelus solutions are designed specifically for scalable public health deployment.

• Low-cost
• Portable
• Offline capable
• Easy to operate
• Built for mass screening

Artelus states that its products and organization are CE and ISO certified.

Yes. Artelus highlights imaging capabilities on non-dilated pupils in daylight settings.

Artelus offers fundus imaging devices including NFC-700 and NFC-600 systems with automated image capture and AI integration.

Artelus is designed to improve both clinical efficiency and accessibility. Its solutions can help ophthalmologists streamline screening workflows while expanding access to retinal imaging.

• Faster screening workflows
• Strong return on investment
• Portable imaging
• AI-assisted diagnostics
• Lower operational burden
• High-quality retinal imaging
• Reduced dependency on skilled operators
• Better outreach capabilities

Artelus enables retinal screening in less than 1–2 minutes per patient, helping clinics improve efficiency and patient throughput.

• Increase patient throughput
• Reduce waiting time
• Improve efficiency
• Optimize staff utilization
• Deliver faster turnaround

In most patients, no dilatation is required. Artelus supports truly non-mydriatic imaging, reducing the complexity of the screening workflow.

• Patient discomfort
• Screening time
• Workflow complexity
• Need for dark room setup

The Artelus NFC is an AI-powered fundus imaging system designed for fast, operator-independent retinal screening. It combines automated image capture with AI-assisted analysis.

The Artelus NFC Fundus Camera provides automated, portable, and AI-assisted retinal imaging capabilities.

• 12 MP high-definition retinal imaging
• Operator-independent workflow
• Fully automated image capture
• Non-mydriatic imaging
• No dark room requirement
• Offline AI
• Fast screening time
• Battery-operated functionality
• Portable design
• Real-time AI reporting

Yes. Artelus devices are battery-operated, enabling uninterrupted operation during power outages.

Yes. Artelus systems are designed for scalability across multiple healthcare and public health environments.

• Hospital networks
• Diagnostic chains
• Satellite clinics
• Public health programs
• Teleophthalmology initiatives

Yes. Artelus systems are designed to be highly operator-independent and can be operated by minimally trained personnel after brief onboarding.

• Auto-sensing
• Auto-alignment
• Auto-focus
• Auto flash adjustment
• Auto-capture

Early retinal screening helps identify vision-threatening conditions before symptoms become severe. Timely detection of diseases such as diabetic retinopathy and DME can help reduce the risk of preventable vision loss and support better long-term eye health outcomes.

Yes. Artelus is taking AI-powered eye screening to remote and underserved communities across India. Its AI-based screening solutions, including DRISTi AI, are designed to support retinal screening in community settings, including locations where continuous internet connectivity may not be available. Through screening camps and community initiatives, Artelus is helping bring early eye screening closer to the people who need it most.

To learn more or schedule a demo, contact Artelus or visit the official websites.